1
|
Lu CM, Yang YS, Lu YM, Zhu YP, Zhang A, Lyu SC, Zhang JP. Qishen Yiqi Dripping Pills for Cardiovascular Diseases: Effects and Mechanisms. Chin J Integr Med 2023; 29:857-864. [PMID: 36301453 DOI: 10.1007/s11655-022-3288-2] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 01/11/2020] [Indexed: 11/30/2022]
Abstract
Qishen Yiqi Dripping Pills (QSYQ) is a compound of Chinese medicine, which has been used to treat coronary heart disease and cardiac dysfunction. Its natural components include astragaloside IV, flavonoids, danshensu, protocatechualdehyde, salvianolic acid B, salvianolic acid A, ginsenosides Rg1, ginsenosides Rb1, and essential oils, etc. It exerts effects of nourishing qi and promoting blood circulation to relieve pain. In this review, the bioactive components of QSYQ and its effects for treating cardiovascular diseases and possible mechanism were summarized, providing references for further study and clinical application of QSYQ.
Collapse
Affiliation(s)
- Chun-Miao Lu
- Department of Cardiovascular Medicine, First Teaching Hospital of Tianjin University of Traditional Chinese Medicine, Tianjin, 300193, China
| | - Yu-Song Yang
- Graduate School, Tianjin University of Traditional Chinese Medicine, Tianjin, 300193, China
| | - Yan-Min Lu
- Institute of Acute Abdominal Diseases, Nankai Hospital, Tianjin, 300100, China
| | - Ya-Ping Zhu
- Department of Cardiovascular Medicine, First Teaching Hospital of Tianjin University of Traditional Chinese Medicine, Tianjin, 300193, China
| | - Ao Zhang
- Epidemiology, College of Global Public Health, New York University, New York, 10003, USA
| | - Shi-Chao Lyu
- Department of Geriatric Medicine, First Teaching Hospital of Tianjin University of Traditional Chinese Medicine, Tianjin, 300193, China.
| | - Jun-Ping Zhang
- Department of Geriatric Medicine, First Teaching Hospital of Tianjin University of Traditional Chinese Medicine, Tianjin, 300193, China
| |
Collapse
|
2
|
Liu M, Long X, Xu J, Chen M, Yang H, Guo X, Kang J, Ouyang Y, Luo G, Yang S, Zhou H. Hypertensive heart disease and myocardial fibrosis: How traditional Chinese medicine can help addressing unmet therapeutical needs. Pharmacol Res 2022; 185:106515. [DOI: 10.1016/j.phrs.2022.106515] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 09/10/2022] [Revised: 10/07/2022] [Accepted: 10/13/2022] [Indexed: 11/26/2022]
|
3
|
Zhao C, Wang W, Yan K, Sun H, Han J, Hu Y. The therapeutic effect and mechanism of Qishen Yiqi dripping pills on cardiovascular and cerebrovascular diseases and diabetic complications. Curr Mol Pharmacol 2021; 15:547-556. [PMID: 34382512 DOI: 10.2174/1874467214666210811153610] [Citation(s) in RCA: 3] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/04/2021] [Revised: 05/30/2021] [Accepted: 06/25/2021] [Indexed: 11/22/2022]
Abstract
The alterations in vascular homeostasis is deeply involved in the development of numerous diseases, such as coronary heart disease, stroke, and diabetic complications. Changes in blood flow and endothelial permeability caused by vascular dysfunction are the common mechanisms for these three types of diseases. The disorders of glucose and lipid metabolism can result in changes of the energy production patterns in endothelium and surrounding cells which may consequently cause local energy metabolic disorders, oxidative stress and inflammatory responses. Traditional Chinese medicine (TCM) follows the principle of the "treatment by the syndrome differentiation". TCM considers of that coronary heart disease, stroke and diabetes complications all as the type of "Qi deficiency and Blood stasis" syndrome, which mainly happens to the vascular system. Therefore, the common pathogenesis of these three types of diseases suggests the treatment strategy by TCM should be in a close manner and named as "treating different diseases by the same treatment". Qishen Yiqi dripping pills is a modern Chinese herbal medicine which has been widely used for treatment of patients with coronary heart disease characterized as "Qi deficiency and blood stasis" in China. Recently, many clinical reports have demonstrated the potent therapeutic effects of Qishen Yiqi dripping pills on ischemic stroke and diabetic nephropathy. Based on these reports, we will summarize the clinical applications of Qishen Yiqi dripping pills on coronary heart disease, ischemic stroke and diabetic nephropathy, including the involved mechanisms with basic researches.
Collapse
Affiliation(s)
- Chunlai Zhao
- GeneNet Pharmaceuticals Co. Ltd., Tianjin. China
| | - Wenjia Wang
- GeneNet Pharmaceuticals Co. Ltd., Tianjin. China
| | - Kaijing Yan
- GeneNet Pharmaceuticals Co. Ltd., Tianjin. China
| | - He Sun
- GeneNet Pharmaceuticals Co. Ltd., Tianjin. China
| | - Jihong Han
- Department of Biochemistry and Molecular Biology, College of Life Sciences, State Key Laboratory of Medicinal Chemical Biology, Key Laboratory of Bioactive Materials of Ministry of Education, Nankai University, Tianjin. China
| | - Yunhui Hu
- GeneNet Pharmaceuticals Co. Ltd., Tianjin. China
| |
Collapse
|
4
|
QiShenYiQi Pill Improves Myocardial Hypertrophy Caused by Pressure Overload in Rats. EVIDENCE-BASED COMPLEMENTARY AND ALTERNATIVE MEDICINE 2021; 2021:5536723. [PMID: 34221074 PMCID: PMC8225423 DOI: 10.1155/2021/5536723] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Received: 01/26/2021] [Revised: 05/17/2021] [Accepted: 06/07/2021] [Indexed: 01/19/2023]
Abstract
Pressure-overloaded myocardial hypertrophy is an independent risk factor for various cardiovascular diseases (CVDs), such as heart failure (HF), arrhythmia, and even sudden death. It is reported that QiShenYiQi pill (QSYQ) is widely used in the treatment of CVDs and can prevent pathological hypertrophy of myocardium, but its specific mechanism is still unclear. In this study, a rat model of myocardial hypertrophy was established through the pressure overload caused by abdominal aortic constriction in Wistar rats. The rats were randomly divided into model group, valsartan group, and QSYQ group, and sham-operated animals served as the control group. At the 4 and 8 weeks of intervention, the general morphology of the heart, myocardial collagen content, collagen volume factor (CVF), collagen type I, collagen type III, myocardial pathological changes, and the expression of ANP, β-MHC, TGF-β1, and CTGF were analyzed, respectively, in order to explore the possible effect of QSYQ on the mechanism of myocardial hypertrophy. We observed that QSYQ could effectively improve myocardial hypertrophy in pressure-overloaded rats, which was related to the regulatory mechanism of TGF-β1 and CTGF.
Collapse
|
5
|
Lv S, Yuan P, Lu C, Dong J, Li M, Qu F, Zhu Y, Zhang J. QiShenYiQi pill activates autophagy to attenuate reactive myocardial fibrosis via the PI3K/AKT/mTOR pathway. Aging (Albany NY) 2021; 13:5525-5538. [PMID: 33582656 PMCID: PMC7950250 DOI: 10.18632/aging.202482] [Citation(s) in RCA: 6] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/27/2020] [Accepted: 11/20/2020] [Indexed: 01/08/2023]
Abstract
QiShenYiQi pill (QSYQ), a traditional Chinese medicine, is used to treat cardiovascular diseases. However, the dose-effect relationship of its intervention in the reactive myocardial fibrosis is elusive. In this work, rat models of reactive myocardial fibrosis induced by partial abdominal aortic coarctation were constructed and randomly classified into the model group, 3-methyladenine group, rapamycin group, QSYQ low-dose group, QSYQ medium-dose group, QSYQ high-dose group, and sham-operated rats (control group). We revealed that QSYQ lowered the heart mass index (HMI), left ventricular mass index (LVMI), and myocardial collagen volume fraction (CVF) levels in a dose-dependent mechanism. Additionally, QSYQ increased the number of autophagosomes, and the expression of myocardial Beclin-1 and LC3B. In contrast, it reduced the expression of myocardial p62 and decreased the ratios of myocardial p-PI3K/PI3K, p-Akt/Akt, and p-mTOR/mTOR. In conclusion, our results have revealed that QSYQ impacts anti-reactive myocardial fibrosis in a dose-dependent mechanism which is mediated by the activation of myocardial autophagy via the PI3K/AKT/mTOR pathway.
Collapse
Affiliation(s)
- Shichao Lv
- First Teaching Hospital of Tianjin University of Traditional Chinese Medicine, Tianjin 300193, China
- Tianjin Key Laboratory of Traditional Research of TCM Prescription and Syndrome, Tianjin 300193, China
| | - Peng Yuan
- First Teaching Hospital of Tianjin University of Traditional Chinese Medicine, Tianjin 300193, China
| | - Chunmiao Lu
- Jiashan Hospital of Traditional Chinese Medicine, Jiaxing 314100, Zhejiang, China
| | - Jianping Dong
- Health Center of Balitai Town, Jinnan, Tianjin 300350, China
| | - Meng Li
- First Teaching Hospital of Tianjin University of Traditional Chinese Medicine, Tianjin 300193, China
| | - Fan Qu
- First Teaching Hospital of Tianjin University of Traditional Chinese Medicine, Tianjin 300193, China
| | - Yaping Zhu
- First Teaching Hospital of Tianjin University of Traditional Chinese Medicine, Tianjin 300193, China
| | - Junping Zhang
- First Teaching Hospital of Tianjin University of Traditional Chinese Medicine, Tianjin 300193, China
| |
Collapse
|
6
|
Lv S, Yuan P, Dong J, Lu C, Li M, Qu F, Zhu Y, Yuan Z, Zhang J. QiShenYiQi pill improves the reparative myocardial fibrosis by regulating autophagy. J Cell Mol Med 2020; 24:11283-11293. [PMID: 32881330 PMCID: PMC7576289 DOI: 10.1111/jcmm.15695] [Citation(s) in RCA: 7] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/08/2020] [Revised: 06/17/2020] [Accepted: 07/10/2020] [Indexed: 12/12/2022] Open
Abstract
QiShenYiQi pill (QSYQ), a traditional Chinese medicine, is well known for improving the myocardial remodelling, but the dose‐effect relationship of its intervention in the reparative myocardial fibrosis is still unclear. We investigated the effect of QSYQ on the reparative myocardial fibrosis in cardiac myosin‐induced rats and explored its mechanism of action by regulating autophagy. The results indicated that QSYQ increased LVEF and LVFS, and decreased the LVEDD, LVESD, HMI, LVMI, myocardial inflammation histology score, and collagen volume fraction in a dose‐dependent manner. In addition, QSYQ declined the number of autophagosomes, down‐regulated the expression of myocardial Beclin‐1 and LC3B, up‐regulated the expression of myocardial p62 and increased the ratios of myocardial p‐PI3K/PI3K, p‐Akt/Akt and p‐mTOR/mTOR. We provided evidence for that QSYQ could inhibit excessive myocardial autophagy by regulating the PI3K/Akt‐mTOR pathway and can be a potential therapeutic approach in treating the cardiovascular diseases such as myocarditis and dilated cardiomyopathy.
Collapse
Affiliation(s)
- Shichao Lv
- First Teaching Hospital of Tianjin University of Traditional Chinese Medicine, Tianjin, China.,Tianjin Key Laboratory of Traditional Research of TCM Prescription and Syndrome, Tianjin, China
| | - Peng Yuan
- First Teaching Hospital of Tianjin University of Traditional Chinese Medicine, Tianjin, China
| | | | - Chunmiao Lu
- Jiashan Hospital of Traditional Chinese Medicine, Jiaxing, China
| | - Meng Li
- First Teaching Hospital of Tianjin University of Traditional Chinese Medicine, Tianjin, China
| | - Fan Qu
- First Teaching Hospital of Tianjin University of Traditional Chinese Medicine, Tianjin, China
| | - Yaping Zhu
- First Teaching Hospital of Tianjin University of Traditional Chinese Medicine, Tianjin, China
| | - Zhuo Yuan
- First Teaching Hospital of Tianjin University of Traditional Chinese Medicine, Tianjin, China
| | - Junping Zhang
- First Teaching Hospital of Tianjin University of Traditional Chinese Medicine, Tianjin, China
| |
Collapse
|
7
|
Zhang S, Wang H, Li L, Chang X, Ma H, Zhang M, Qing X, Zhang L, Zhang Z. Qishen Yiqi Drop Pill, a novel compound Chinese traditional medicine protects against high glucose-induced injury in cardiomyocytes. J Cell Mol Med 2019; 23:6393-6402. [PMID: 31278860 PMCID: PMC6714141 DOI: 10.1111/jcmm.14527] [Citation(s) in RCA: 13] [Impact Index Per Article: 2.6] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/02/2018] [Revised: 05/17/2019] [Accepted: 06/19/2019] [Indexed: 01/20/2023] Open
Abstract
OBJECTIVE Qishen Yiqi Drop Pill (QSYQ) has been recognized as a potential protective agent for various cardiovascular diseases. However, the effect of QSYQ in cardiac complications associated with diabetes is not clear currently. In this study, we investigate whether QSYQ could exert cardiac protective effects against high glucose-induced injuries in cardiac H9c2 cells. METHODS H9c2 cells were exposed to 24 hours of high glucose in presence or absence of QSYQ and LY294002. Cell cytotoxicity, apoptosis, reactive oxygen species (ROS) generation, mitochondrial membrane potential and mitochondrial permeability transition pore (mPTP) opening were determined. Levels of bax, bcl-2, p53, cleaved caspase-3, PI3K and Akt were evaluated by Western blot. RESULTS Our data indicated that QSYQ significantly increased the cell viability and decreased cytotoxicity. By analysing the apoptotic rate as well as the expression levels of cytoapoptosis-related factors including cleaved caspase-3, bax, bcl-2, and p53, we found that QSYQ could remarkably suppress apoptosis of cardiomyoblasts caused by high glucose. In addition, it also showed that QSYQ reduced the generation of ROS. We further found that QSYQ treatment could inhibit the loss of mitochondrial membrane potential and mPTP opening. Moreover, Western blot analysis showed enhanced phosphorylation of PI3K/Akt. The specific inhibitor of PI3K, LY294002 not only inhibited QSYQ induced PI3K/Akt signalling pathway activation, but alleviated its protective effects. CONCLUSIONS In summary, these findings demonstrated that QSYQ effectively protected H9c2 cells against the series injuries due to high glucose at least partially by activating the PI3K/Akt signalling pathway.
Collapse
Affiliation(s)
- Shouyan Zhang
- Department of Cardiology, Luoyang Central Hospital Affiliated to Zhengzhou University, Luoyang Institute of Cardio-cerebrovascular Diseases, Luoyang Key Laboratory of Cardiac-cerebro Tissue Injury and Repair, Luoyang, China
| | - Hao Wang
- Department of Cardiology, Luoyang Central Hospital Affiliated to Zhengzhou University, Luoyang Institute of Cardio-cerebrovascular Diseases, Luoyang Key Laboratory of Cardiac-cerebro Tissue Injury and Repair, Luoyang, China
| | - Lixia Li
- Department of Cardiology, Luoyang Central Hospital Affiliated to Zhengzhou University, Luoyang Institute of Cardio-cerebrovascular Diseases, Luoyang Key Laboratory of Cardiac-cerebro Tissue Injury and Repair, Luoyang, China
| | - Xuewei Chang
- Department of Cardiology, Luoyang Central Hospital Affiliated to Zhengzhou University, Luoyang Institute of Cardio-cerebrovascular Diseases, Luoyang Key Laboratory of Cardiac-cerebro Tissue Injury and Repair, Luoyang, China
| | - Huifang Ma
- Department of Cardiology, Luoyang Central Hospital Affiliated to Zhengzhou University, Luoyang Institute of Cardio-cerebrovascular Diseases, Luoyang Key Laboratory of Cardiac-cerebro Tissue Injury and Repair, Luoyang, China
| | - Mingming Zhang
- Department of Cardiology, Luoyang Central Hospital Affiliated to Zhengzhou University, Luoyang Institute of Cardio-cerebrovascular Diseases, Luoyang Key Laboratory of Cardiac-cerebro Tissue Injury and Repair, Luoyang, China
| | - Xiaochun Qing
- Department of Cardiology, Luoyang Central Hospital Affiliated to Zhengzhou University, Luoyang Institute of Cardio-cerebrovascular Diseases, Luoyang Key Laboratory of Cardiac-cerebro Tissue Injury and Repair, Luoyang, China
| | - Lijun Zhang
- Department of Cardiology, Luoyang Central Hospital Affiliated to Zhengzhou University, Luoyang Institute of Cardio-cerebrovascular Diseases, Luoyang Key Laboratory of Cardiac-cerebro Tissue Injury and Repair, Luoyang, China
| | - Zhuo Zhang
- Department of Cardiology, Luoyang Central Hospital Affiliated to Zhengzhou University, Luoyang Institute of Cardio-cerebrovascular Diseases, Luoyang Key Laboratory of Cardiac-cerebro Tissue Injury and Repair, Luoyang, China
| |
Collapse
|
8
|
Ruan G, Ren H, Zhang C, Zhu X, Xu C, Wang L. Cardioprotective Effects of QiShenYiQi Dripping Pills on Transverse Aortic Constriction-Induced Heart Failure in Mice. Front Physiol 2018; 9:324. [PMID: 29666587 PMCID: PMC5891926 DOI: 10.3389/fphys.2018.00324] [Citation(s) in RCA: 17] [Impact Index Per Article: 2.8] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/14/2017] [Accepted: 03/15/2018] [Indexed: 12/18/2022] Open
Abstract
QiShenYiQi dripping pills (QSYQ), a traditional Chinese medicine, are commonly used to treat coronary heart disease, and QSYQ was recently approved as a complementary treatment for ischemic heart failure in China. However, only few studies reported on whether QSYQ exerts a protective effect on heart failure induced by pressure overload. In this study, we explored the role of QSYQ in a mouse model of heart failure induced by transverse aortic constriction (TAC). Twenty-eight C57BL/6J mice were divided into four groups: Sham + NS group, Sham + QSYQ group, TAC + NS group, and TAC + QSYQ group. QSYQ dissolved in normal saline (NS) was administered intragastrically (3.5 mg/100 g/day) in the Sham + QSYQ and TAC + QSYQ groups. In the Sham + NS and TAC + NS groups, NS was provided every day intragastrically. Eight weeks after TAC, echocardiography, and cardiac catheterization were performed to evaluate the cardiac function, and immunofluorescent staining with anti-actinin2 antibody was performed to determine the structure of the myocardial fibers. Moreover, TUNEL staining and Masson trichrome staining were employed to assess the effects of QSYQ on cardiac apoptosis and cardiac fibrosis. Western blots and real-time polymerase chain reaction (PCR) were used to measure the expression levels of vascular endothelial growth factor (VEGF) in the heart, and immunohistochemical staining with anti-CD31 antibody was performed to explore the role of QSYQ in cardiac angiogenesis. Results showed that TAC-induced cardiac dysfunction and disrupted structure of myocardial fibers significantly improved after QSYQ treatment. Moreover, QSYQ treatment also significantly improved cardiac apoptosis and cardiac fibrosis in TAC-induced heart failure, which was accompanied by an increase in VEGF expression levels and maintenance of microvessel density in the heart. In conclusion, QSYQ exerts a protective effect on TAC-induced heart failure, which could be attributed to enhanced cardiac angiogenesis, which is closely related to QSYQ. Thus, QSYQ may be a promising traditional Chinese medicine for the treatment of heart failure induced by pressure overload such as hypertension.
Collapse
Affiliation(s)
- Guoran Ruan
- Department of Cardiology, The Puren Hospital, Wuhan University of Science and Technology, Wuhan, China
| | - Haojin Ren
- Department of Cardiology, The Puren Hospital, Wuhan University of Science and Technology, Wuhan, China
| | - Chi Zhang
- Department of Cardiology, The Puren Hospital, Wuhan University of Science and Technology, Wuhan, China
| | - Xiaogang Zhu
- Department of Cardiology, The Puren Hospital, Wuhan University of Science and Technology, Wuhan, China
| | - Chao Xu
- Department of Cardiology, The Puren Hospital, Wuhan University of Science and Technology, Wuhan, China
| | - Liyue Wang
- Department of Cardiology, The Puren Hospital, Wuhan University of Science and Technology, Wuhan, China
| |
Collapse
|
9
|
Zheng X, Wang S, Zou X, Jing Y, Yang R, Li S, Wang F. Ginsenoside Rb1 improves cardiac function and remodeling in heart failure. Exp Anim 2017; 66:217-228. [PMID: 28367863 PMCID: PMC5543242 DOI: 10.1538/expanim.16-0121] [Citation(s) in RCA: 66] [Impact Index Per Article: 9.4] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/17/2022] Open
Abstract
We investigated the effect of ginsenoside Rb1 on cardiac function and remodeling in heart
failure (HF). Four weeks after HF induction, the rats were administrated with ginsenoside
Rb1 (35 and 70 mg/kg) and losartan (4.5 mg/kg) for 8 weeks. Losartan was used as a
positive control. Cardiac function was assessed by measuring hemodynamic parameters.
Histological changes were analyzed by HE and Masson’s trichrome staining. Cardiac
hypertrophy, fibrosis, mitochondrial membrane potential and glucose transporter type 4
(GLUT4) levels were evaluated. In the present study, high dose of (H−) ginsenoside Rb1
decreased heart rate, improved cardiac function and alleviated histological changes
induced by HF. H-ginsenoside Rb1 attenuated cardiac hypertrophy and myocardial fibrosis by
decreasing left ventricular (LV) weight/heart weight ratio and cardiomyocyte
cross-sectional area and reducing the levels of atrial natriuretic factor (ANF), β-myosin
heavy chain (β-MHC), periostin, collagen I, Angiotensin II (Ang II), Angiotensin
converting enzyme (ACE) and Ang II type 1 (AT1) receptor. Moreover, H-ginsenoside Rb1
decreased mitochondrial membrane potential and enhanced the translocation of GLUT4 to
plasma membrane. The TGF-β1/Smad and ERK signaling pathways were inhibited and the Akt
pathway was activated. These findings suggest that ginsenoside Rb1 might restore
cardiac/mitochondrial function, increase glucose uptake and protect against cardiac
remodeling via the TGF-β1/Smad, ERK and Akt signaling pathways.
Collapse
Affiliation(s)
- Xian Zheng
- Graduate School, Liaoning University of Traditional Chinese Medicine, 79 Chongshan East Road, Shenyang 110847, P.R. China
| | - Shuai Wang
- First Department of Cardiology, The Affiliated Hospital of Liaoning University of Traditional Chinese Medicine, 33 Beiling Avenue, Shenyang 110032, P.R. China
| | - Xiaoming Zou
- Graduate School, Liaoning University of Traditional Chinese Medicine, 79 Chongshan East Road, Shenyang 110847, P.R. China
| | - Yating Jing
- First Department of Cardiology, The Affiliated Hospital of Liaoning University of Traditional Chinese Medicine, 33 Beiling Avenue, Shenyang 110032, P.R. China
| | - Ronglai Yang
- First Department of Cardiology, The Affiliated Hospital of Liaoning University of Traditional Chinese Medicine, 33 Beiling Avenue, Shenyang 110032, P.R. China
| | - Siqi Li
- Standardization Office, The Affiliated Hospital of Liaoning University of Traditional Chinese Medicine, 33 Beiling Avenue, Shenyang 110032, P.R. China
| | - Fengrong Wang
- First Department of Cardiology, The Affiliated Hospital of Liaoning University of Traditional Chinese Medicine, 33 Beiling Avenue, Shenyang 110032, P.R. China
| |
Collapse
|
10
|
Lv SC, Wu M, Li M, Wang Q, Wang XJ, Zhang A, Xu L, Zhang JP. Effect of QiShenYiQi pill on myocardial collagen metabolism in experimental autoimmune myocarditis rats. Biomed Pharmacother 2017; 88:894-901. [PMID: 28178619 DOI: 10.1016/j.biopha.2017.01.096] [Citation(s) in RCA: 8] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/22/2016] [Revised: 12/23/2016] [Accepted: 01/16/2017] [Indexed: 02/02/2023] Open
Abstract
OBJECTIVE To observe the effect of QiShenYiQi pill (QSYQ) on myocardial collagen metabolism in experimental autoimmune myocarditis rats, and to explore its mechanism of action. METHODS Lewis rats underwent the injection of myocardial myosin mixed with freund's complete adjuvant were randomized into three groups: model, valsartan and QSYQ groups. And we treated rats which were injected phosphate buffered saline (PBS) mixed with freund's complete adjuvant as control group. Rats were intervened and euthanized at 4 and 8 weeks. We use alkaline hydrolysis to detect the content of myocardial hydroxyproline (HYP), and ELISA to detect the level of serum procollagen type I carboxyterminal peptide (PICP), procollagen type III amino-terminal peptide (PIIINP), and collagen C telopeptide type I (CTX-I). Myocardial MMP-1 and TIMP-1 protein expression was detected by immunohistochemistry, and myocardial MMP-1 and TIMP-1 mRNA expression was detected by real-time qPCR. RESULTS QSYQ reduced the content of myocardial HYP, and this reduction was greater over time. QSYQ also reduced the serum concentration of PICP, PIIINP, CTX-I and the PICP/PIIINP ratio, which further reduced over time, whereas its effect on lowering PICP was significantly greater than that of valsartan at 4 and 8 weeks, and lowering CTX-I was significantly greater than that of valsartan at 8 weeks. In addition, after 4 weeks, QSYQ enhanced the protein and mRNA expression of MMP-1 and TIMP-1, and its effect on highering TIMP-1 was significantly greater than that of valsartan, whereas there was no significant difference in the expression of myocardial MMP-1 or TIMP-1 at 8 weeks. QSYQ reduced the ratio of MMP-1/TIMP-1, which further reduced over time, and the effect of QYSQ was significantly greater than that of valsartan after 4 weeks. CONCLUSION This study provides evidence that QSYQ can reduce the rate of myocardial collagen synthesis and degradation. It also effectively improved the degree of myocardial fibrosis in experimental autoimmune myocarditis rats and it had a tendency to have a greater effect with longer treatment duration, which is related to the mechanism of regulation of MMP-1 and TIMP-1 expression in the myocardial rat.
Collapse
Affiliation(s)
- Shi-Chao Lv
- Department of Geriatric Medicine, First Teaching Hospital of Tianjin University of Traditional Chinese Medcine, 314 An Shan Xi Road, Nan Kai District, Tianjin, 300193, China
| | - Meifang Wu
- Tianjin University of Traditional Chinese Medcine, 312 An Shan Xi Road, Nan Kai District, Tianjin, 300193, China
| | - Meng Li
- Tianjin University of Traditional Chinese Medcine, 312 An Shan Xi Road, Nan Kai District, Tianjin, 300193, China
| | - Qiang Wang
- Tianjin University of Traditional Chinese Medcine, 312 An Shan Xi Road, Nan Kai District, Tianjin, 300193, China
| | - Xiao-Jing Wang
- Tianjin University of Traditional Chinese Medcine, 312 An Shan Xi Road, Nan Kai District, Tianjin, 300193, China
| | - Ao Zhang
- School of Integrative Medicine, Tianjin University of Traditional Chinese Medcine, 312 An Shan Xi Road, Nan Kai District, Tianjin, 300193, China
| | - Ling Xu
- Tianjin University of Traditional Chinese Medcine, 312 An Shan Xi Road, Nan Kai District, Tianjin, 300193, China
| | - Jun-Ping Zhang
- Department of Geriatric Medicine, First Teaching Hospital of Tianjin University of Traditional Chinese Medcine, 314 An Shan Xi Road, Nan Kai District, Tianjin, 300193, China.
| |
Collapse
|
11
|
Zhou Z, Hu Z, Li M, Zhu F, Zhang H, Nie J, Ai J. QiShenYiQi Attenuates Renal Interstitial Fibrosis by Blocking the Activation of β-Catenin. PLoS One 2016; 11:e0162873. [PMID: 27636716 PMCID: PMC5026381 DOI: 10.1371/journal.pone.0162873] [Citation(s) in RCA: 9] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/06/2015] [Accepted: 08/26/2016] [Indexed: 01/11/2023] Open
Abstract
Chronic kidney disease (CKD) is becoming a worldwide problem. However, current treatment options are limited. In the current study we showed that QiShenYiQi (QSYQ), a water-ethanol extract from several Chinese medicines, is a potent inhibitor of renal interstitial fibrosis. QSYQ inhibited transforming growth factor-β1 (TGF-β1)-responsive α-smooth muscle actin (α-SMA), collagen I, and fibronectin up-regulation in obstructive nephropathy and cultured cells. Administration of QSYQ also inhibited the established renal interstitial fibrosis in obstructive nephropathy. Interestingly, QSYQ selectively inhibited TGF-β1-induced β-catenin up-regulation and downstream gene transcription. Taken together, our study suggests that QSYQ selectively inhibits TGF-β1-induced β-catenin up-regulation and might have significant therapeutic potential for the treatment of renal fibrosis.
Collapse
Affiliation(s)
- Zhanmei Zhou
- State Key Laboratory of Organ Failure Research, National Clinical Research Center of Kidney Disease, Division of Nephrology, Nanfang Hospital, Southern Medical University, Guangzhou, P.R. China
| | - Zheng Hu
- State Key Laboratory of Organ Failure Research, National Clinical Research Center of Kidney Disease, Division of Nephrology, Nanfang Hospital, Southern Medical University, Guangzhou, P.R. China
| | - Mei Li
- State Key Laboratory of Organ Failure Research, National Clinical Research Center of Kidney Disease, Division of Nephrology, Nanfang Hospital, Southern Medical University, Guangzhou, P.R. China
| | - Fengxin Zhu
- State Key Laboratory of Organ Failure Research, National Clinical Research Center of Kidney Disease, Division of Nephrology, Nanfang Hospital, Southern Medical University, Guangzhou, P.R. China
| | - Hao Zhang
- Tasly R&D Institute, Tianjin, P.R. China
| | - Jing Nie
- State Key Laboratory of Organ Failure Research, National Clinical Research Center of Kidney Disease, Division of Nephrology, Nanfang Hospital, Southern Medical University, Guangzhou, P.R. China
| | - Jun Ai
- State Key Laboratory of Organ Failure Research, National Clinical Research Center of Kidney Disease, Division of Nephrology, Nanfang Hospital, Southern Medical University, Guangzhou, P.R. China
| |
Collapse
|
12
|
Wang J, Li C, Cao Y, Wang Q, Lu L, Chang H, Wu Y, Han J, Wang W, Tu P, Wang Y. Mechanism of QSYQ on anti-apoptosis mediated by different subtypes of cyclooxygenase in AMI induced heart failure rats. BMC COMPLEMENTARY AND ALTERNATIVE MEDICINE 2015; 15:352. [PMID: 26445960 PMCID: PMC4597456 DOI: 10.1186/s12906-015-0869-z] [Citation(s) in RCA: 17] [Impact Index Per Article: 1.9] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Received: 04/04/2015] [Accepted: 09/21/2015] [Indexed: 01/31/2023]
Abstract
Background Qi-shen-yi-qi (QSYQ), one of the most well-known traditional Chinese medicine (TCM) formulas, has been shown to have cardioprotective effects in rats with heart failure (HF) induced by acute myocardial infarction (AMI). However, the mechanisms of its therapeutic effects remain unclear. In this study, we aim to explore the mechanisms of QSYQ in preventing left ventricular remodelling in rats with HF. The anti-apoptosis an anti-inflammation effects of QSYQ were investigated. Methods Sprague–Dawley (SD) rats were randomly divided into 4 groups: sham group, model group, QSYQ treatment group and aspirin group. Heart failure model was induced by ligation of left anterior descending (LAD) coronary artery. 28 days after surgery, hemodynamics were detected. Echocardiography was adopted to evaluate heart function. TUNEL assay was applied to assess myocardial apoptosis rates. Protein expressions of cyclooxygenase1 and 2 (COX1and COX2), Fas ligand (FasL), P53 and MDM2 were measured by western-blot. RT-PCR was applied to detect expressions of our subtype receptors of PGE2 (EP1, 2, 3, and 4). Results Ultrasonography showed that EF and FS values decreased significantly and abnormal hemodynamic alterations were observed in model group compared to sham group. These indications illustrated that HF models were successfully induced. Levels of inflammatory cytokines (TNF-α and IL-6) in myocardial tissue were up-regulated in the model group as compared to those in sham group. Western-blot analysis showed that cyclooxygenase 2, which is highly inducible by inflammatory cytokines, increased significantly. Moreover, RT-PCR showed that expressions of EP2 and EP4, which are the receptors of PGE2, were also up-regulated. Increased expressions of apoptotic pathway factors, including P53 and FasL, might be induced by the binding of PGE2 with EP2/4. MDM2, the inhibitor of P53, decreased in model group. TUNEL results manifested that apoptosis rates of myocardial cells increased in the model group. After treatment with QSYQ, expressions of inflammatory factors, including TNF-α, IL-6 and COX2, were reduced. Expressions of EP2 and EP4 receptors also decreased, suggesting that PGE2-mediated apoptosis was inhibited by QSYQ. MDM2 was up-regulated and P53 and FasL in the apoptotic pathway were down-regulated. Apoptosis rates in myocardial tissue in the QSYQ group decreased compared with those in the model group. Conclusions QSYQ exerts cardiac protective efficacy mainly through inhibiting the inflammatory response and down-regulating apoptosis. The anti-inflammatory and anti-apoptosis efficacies of QSYQ are probably achieved by inhibition of COXs-induced P53/FasL pathway. These findings provide experimental evidence for the beneficial effects of QSYQ in the clinical application for treating patients with HF. Electronic supplementary material The online version of this article (doi:10.1186/s12906-015-0869-z) contains supplementary material, which is available to authorized users.
Collapse
|
13
|
Chen YY, Li Q, Pan CS, Yan L, Fan JY, He K, Sun K, Liu YY, Chen QF, Bai Y, Wang CS, He B, Lv AP, Han JY. QiShenYiQi Pills, a compound in Chinese medicine, protects against pressure overload-induced cardiac hypertrophy through a multi-component and multi-target mode. Sci Rep 2015; 5:11802. [PMID: 26136154 PMCID: PMC4488877 DOI: 10.1038/srep11802] [Citation(s) in RCA: 44] [Impact Index Per Article: 4.9] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/01/2015] [Accepted: 06/02/2015] [Indexed: 12/31/2022] Open
Abstract
The present study aimed to explore the holistic mechanism for the antihypertrophic effect of a compound in Chinese medicine, QiShenYiQi Pills (QSYQ) and the contributions of its components to the effect in rats with cardiac hypertrophy (CH). After induction of CH by ascending aortic stenosis, rats were treated with QSYQ, each identified active ingredient (astragaloside IV, 3, 4-dihydroxy-phenyl lactic acid or notoginsenoside R1) from its 3 major herb components or dalbergia odorifera, either alone or combinations, for 1 month. QSYQ markedly attenuated CH, as evidenced by echocardiography, morphology and biochemistry. Proteomic analysis and western blot showed that the majority of differentially expressed proteins in the heart of QSYQ-treated rats were associated with energy metabolism or oxidative stress. Each ingredient alone or their combinations exhibited similar effects as QSYQ but to a lesser extent and differently with astragaloside IV and notoginsenoside R1 being more effective for enhancing energy metabolism, 3, 4-dihydroxy-phenyl lactic acid more effective for counteracting oxidative stress while dalbergia odorifera having little effect on the variables evaluated. In conclusion, QSYQ exerts a more potent antihypertrophic effect than any of its ingredients or their combinations, due to the interaction of its active components through a multi-component and multi-target mode.
Collapse
Affiliation(s)
- Yuan-Yuan Chen
- 1] Department of Integration of Chinese and Western Medicine, School of Basic Medical Sciences, Peking University, Beijing, China [2] Tasly Microcirculation Research Center, Peking University Health Science Center, Beijing, China [3] Key Laboratory of Microcirculation, State Administration of Traditional Chinese Medicine of China, Beijing, China [4] Key Laboratory of Stasis and Phlegm, State Administration of Traditional Chinese Medicine of China, Beijing, China
| | - Quan Li
- 1] Tasly Microcirculation Research Center, Peking University Health Science Center, Beijing, China [2] Key Laboratory of Microcirculation, State Administration of Traditional Chinese Medicine of China, Beijing, China [3] Key Laboratory of Stasis and Phlegm, State Administration of Traditional Chinese Medicine of China, Beijing, China
| | - Chun-Shui Pan
- 1] Tasly Microcirculation Research Center, Peking University Health Science Center, Beijing, China [2] Key Laboratory of Microcirculation, State Administration of Traditional Chinese Medicine of China, Beijing, China [3] Key Laboratory of Stasis and Phlegm, State Administration of Traditional Chinese Medicine of China, Beijing, China
| | - Li Yan
- 1] Tasly Microcirculation Research Center, Peking University Health Science Center, Beijing, China [2] Key Laboratory of Microcirculation, State Administration of Traditional Chinese Medicine of China, Beijing, China [3] Key Laboratory of Stasis and Phlegm, State Administration of Traditional Chinese Medicine of China, Beijing, China
| | - Jing-Yu Fan
- 1] Tasly Microcirculation Research Center, Peking University Health Science Center, Beijing, China [2] Key Laboratory of Microcirculation, State Administration of Traditional Chinese Medicine of China, Beijing, China [3] Key Laboratory of Stasis and Phlegm, State Administration of Traditional Chinese Medicine of China, Beijing, China
| | - Ke He
- 1] Tasly Microcirculation Research Center, Peking University Health Science Center, Beijing, China [2] Key Laboratory of Microcirculation, State Administration of Traditional Chinese Medicine of China, Beijing, China [3] Key Laboratory of Stasis and Phlegm, State Administration of Traditional Chinese Medicine of China, Beijing, China
| | - Kai Sun
- 1] Tasly Microcirculation Research Center, Peking University Health Science Center, Beijing, China [2] Key Laboratory of Microcirculation, State Administration of Traditional Chinese Medicine of China, Beijing, China [3] Key Laboratory of Stasis and Phlegm, State Administration of Traditional Chinese Medicine of China, Beijing, China
| | - Yu-Ying Liu
- 1] Tasly Microcirculation Research Center, Peking University Health Science Center, Beijing, China [2] Key Laboratory of Microcirculation, State Administration of Traditional Chinese Medicine of China, Beijing, China [3] Key Laboratory of Stasis and Phlegm, State Administration of Traditional Chinese Medicine of China, Beijing, China
| | - Qing-Fang Chen
- 1] Department of Integration of Chinese and Western Medicine, School of Basic Medical Sciences, Peking University, Beijing, China [2] Tasly Microcirculation Research Center, Peking University Health Science Center, Beijing, China [3] Key Laboratory of Microcirculation, State Administration of Traditional Chinese Medicine of China, Beijing, China [4] Key Laboratory of Stasis and Phlegm, State Administration of Traditional Chinese Medicine of China, Beijing, China
| | - Yan Bai
- Institute of Vascular Medicine, Peking University Third Hospital and Key Laboratory of Cardiovascular Molecular Biology and Regulatory Peptide, Ministry of Health, Beijing, China
| | - Chuan-She Wang
- 1] Department of Integration of Chinese and Western Medicine, School of Basic Medical Sciences, Peking University, Beijing, China [2] Tasly Microcirculation Research Center, Peking University Health Science Center, Beijing, China [3] Key Laboratory of Microcirculation, State Administration of Traditional Chinese Medicine of China, Beijing, China [4] Key Laboratory of Stasis and Phlegm, State Administration of Traditional Chinese Medicine of China, Beijing, China
| | - Bing He
- The School of Chinese Medicine of Hong Kong Baptist University, Kowloon Tong, Hong Kong, China
| | - Ai-Ping Lv
- The School of Chinese Medicine of Hong Kong Baptist University, Kowloon Tong, Hong Kong, China
| | - Jing-Yan Han
- 1] Department of Integration of Chinese and Western Medicine, School of Basic Medical Sciences, Peking University, Beijing, China [2] Tasly Microcirculation Research Center, Peking University Health Science Center, Beijing, China [3] Key Laboratory of Microcirculation, State Administration of Traditional Chinese Medicine of China, Beijing, China [4] Key Laboratory of Stasis and Phlegm, State Administration of Traditional Chinese Medicine of China, Beijing, China
| |
Collapse
|